Juno Therapeutics Inc

Juno Therapeutics — Investor Presentation (July 2016)

28 slides from Juno Therapeutics's investor presentation, Jul 7, 2016

  1. Slide 1: Exhibit 99.2

    Exhibit 99.2

  2. Slide 2: Forward-looking statements

    Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those exp

  3. Slide 3: Building the leading T cell company

    Building the leading T cell company Significant advances in CD19-directed product candidates with a go-to-market strategy defined in ALL, NHL, and CLL Moving beyond CD19 target with encouraging data in CD22 and WT-1; more targets and approaches in the clinic Progress with potential best-in-class pro

  4. Slide 4: Compelling evidence of rapid tumor shrinkage across multiple clinical trials

    Compelling evidence of rapid tumor shrinkage across multiple clinical trials Day 37 After CD19 CAR T Cells ALL Patient Before CD19 CAR T Cells Day 28 After CD19 CAR T Cells NHL Patient Before CD19 CAR T Cells (1)Across two leukemia trials for defined cell products (JCAR014 and JCAR017) in children a

  5. Slide 5: Significant unmet need in B cell malignancies

    Significant unmet need in B cell malignancies (1)American Cancer Society 2015; Leukemia & Lymphoma Society 2015. Market size numbers from Decision Resources Group. Incidence Annual Deaths ALL NHL CLL/SLL 6,250 42,500 21,080 1,450 19,790 4,650 2015 U.S. Estimates(¹) Market Size ($) $250 Million $3.3

  6. Slide 6: JCAR015 Phase II ROCKET Trial Update

    JCAR015 Phase II ROCKET Trial Update FDA = Food and Drug Administration Two patient deaths within a week due to severe neurotoxicity, following the recent addition of fludarabine (flu) to the pre-conditioning regimen, resulted in a clinical hold. A systematic review of multiple possible factors that

  7. Slide 7: Acute lymphoblastic leukemia (ALL) is an important first market

    Source: Adapted from Decision Resource Group and NCCN. Relapsed/Refractory Chemo, Blincyto, include TKI (Ph+), or clinical trials Relapsed/Refractory Chemo, Blincyto, clinical trials, or palliative care 1st line: Induction/ Consolidation/ Maintenance Relapsed / Refractory Acute lymphoblastic leukemi

  8. Slide 8: Encouraging 65% complete molecular remission as measured by IGH deep sequencing for JCAR014

    Encouraging 65% complete molecular remission as measured by IGH deep sequencing for JCAR014 Juno CD19 experience in ALL Goal Product Candidate Potential First-in-class JCAR015 Potential Best-in-class JCAR017 Translational JCAR014 Trial r/r Adult ALL N = 51 Evaluable = 50 r/r Pediatric ALL N = 42 Eva

  9. Slide 9: Clinical results in ALL show encouraging survival plateaus

    Clinical results in ALL show encouraging survival plateaus Park, ASH 2015 Median OS follow-up: 13 months Historical SOC median survival ~3 months (O’Brien, et al, 2008) JCAR015 Phase 1 Overall Survival With Flu/Cy* CR 22/22 (100%) MRD- CR 22/22 (100%) JCAR014 Phase 1 Overall Survival For JCAR014, in

  10. Slide 10: JCAR018: Increasing selection pressure in B cell malignancies

    JCAR018: Increasing selection pressure in B cell malignancies The two mechanisms for relapse with CD19 CAR T cells are loss of CAR T cells and loss of CD19 CD22-directed CAR addresses CD19 epitope loss Data at AACR were encouraging with 3 of 3 CMRs at dose level 2 with 3 – 6 month follow-up Two clin

  11. Slide 11: DLBCL is a large market opportunity in all lines of therapy

    1Roche Financial Report 2015. Adapted from John Leonard, Weill-Cornell Medical College; *Estimated number of patients (SEER 2015). Relapsed/Refractory Transplant ineligible: chemotherapy Diffuse large B cell lymphoma (DLBCL) is a large market opportunity in all lines of therapy Juno’s goal CHOP-R DL

  12. Slide 12: JCAR014: Encouraging data in NHL

    Conditioning Regimen Flu/Cy Dose Level 2*106/kg N=20 Efficacy CR(1) 10/20 (50%) CR/PR 16/20 (80%) Toxicity Severe Cytokine Release Syndrome 2/20 (10%) Severe Neurotoxicity 2/20 (10%) JCAR014: Encouraging data in NHL NHL Results: Dose Level 2 Progression-Free Survival & Overall Survival For all treat

  13. Slide 13: Juno is building a deep pipeline in NHL

    Goal is best-in-class Juno is building a deep pipeline in NHL JCAR017 Enroll multi-center backbone trial, n = ~70 JCAR014 Phase I (ongoing) Develop translational insights (e.g., lymphodepletion) Test checkpoint inhibitor combination Combination trial with anti-PDL1 CD19 / 4-1BBL Test armored CAR 1 2

  14. Slide 14: Early signal in CLL shows potential for CAR T therapy

    1AbbVie and Johnson & Johnson Financial Reports 2015. Adapted from reports. Patient numbers include CLL and SLL. Watchful waiting 1st-line treatment 2nd-line treatment Early signal in CLL shows potential for CAR T therapy Juno’s goal Newly diagnosed 2015 Sales Estimate1: Imbruvica® = $1.4B 3rd-line

  15. Slide 15: JCAR014: CLL emerging as a significant opportunity

    JCAR014: CLL emerging as a significant opportunity For JCAR014, investigator-reported data as-of May 18, 2016. CR = complete response; PR = partial response Conditioning Regimen Flu/Cy(1) Dose Level All Doses N=11 Efficacy CR(2) 5/11 (45%) CR/PR 10/11 (91%) Toxicity Severe Cytokine Release Syndrome

  16. Slide 16: Significant unmet need in multiple myeloma

    Significant unmet need in multiple myeloma Incidence Annual Deaths Multiple Myeloma 21,320 11,240 U.S. Estimates(¹) $8.9 Billion (1)Incidence and annual deaths from Seer 2015. Market size based on global sales forecast from EvaluatePharma in 2020. (2)Amgen, Celgene, Johnson & Johnson, and Takeda Fin

  17. Slide 17: Multiple myeloma is an emerging pipeline opportunity

    Multiple myeloma is an emerging pipeline opportunity BCMA Target-X Function Binds BAFF and APRIL; Required for plasma cell survival, not generation; interacts with IRF4 XXXXX Expression Post GC B cells to Plasma cells; not memory B cells Mature B cells to Plasma cells Secreted Yes – increased levels

  18. Slide 18: Significant unmet need in solid tumors

    Significant unmet need in solid tumors Incidence Annual Deaths NSCLC (Stage 3b/4) 107,171 132,700 21,920 76,091(2) 49,700 14,180 2015 U.S. Estimates(¹) 88,320 24,000 (1)Incidence and annual deaths obtained through seer.cancer.gov. (2)Incidence represents distant/advance cases (57% of total incidence

  19. Slide 19: Four trials with an opportunity for key learnings in 2016

    Four trials with an opportunity for key learnings in 2016 Applying CAR and TCR technology to solid organ tumors Demonstrate that T cells kill cancer – recent checkpoint inhibitor and tumor infiltrating lymphocytes data Demonstrate that T cells home to the tumor Understand and overcome how the tumor

  20. Slide 20: Apply translational insights to overcome the tumor microenvironment

    Apply translational insights to overcome the tumor microenvironment Checkpoint Inhibitors Modulating T Cell Function pg/ml IL2 Medi 14736 (anti-PDL1) restores CAR T Function “Armored” CARs E:T Ratio

  21. Slide 21: Active programs in clinical development

    Active programs in clinical development The first set of solid tumor targets WT-1 (TCR) AML / NSCLC / Mesothelioma First ongoing partial response reported in refractory mesothelioma at AACR 2016; response correlated to cell expansion and persistence Generally well tolerated and demonstrated early en

  22. Slide 22: Building a category leader

    Building a category leader Manufacturing capabilities JuMP facility online Defined cell product Global reach Celgene collaboration - CD19 opt-in JW Therapeutics - investment in China Research capabilities Internal and BD opportunities Strong balance sheet $1.13 billion as of 1Q16

  23. Slide 23: Manufacturing infrastructure to support patient supply

    Manufacturing infrastructure to support patient supply Facility online to supply clinical material for ongoing Phase II ROCKET trial Capacity for thousands of patients with a scalable and modular design Flexible capacity and able to process multiple products, currently JCAR015 and JCAR017 Functional

  24. Slide 24: Controlling the T cell to improve clinical outcomes

    Controlling the T cell to improve clinical outcomes Juno investing to control the cells that go into and out of our process Biology insights increasingly confirm that the type of T cell matters

  25. Slide 25: Examples of Juno's capabilities

    Cell selection & manipulate extracellular signaling - Stage Targets - Opus Bio / NCI Tumor microenvironment - AstraZeneca / MedImmune Generate binders - AbVitro - X-Body Examples of Juno’s capabilities Capability development to support goal of best-in-class Change DNA - Editas - CAR T technology Mod

  26. Slide 26: Solidifying leadership in the development of transformative immunotherapies

    Solidifying leadership in the development of transformative immunotherapies BUSINESS DEVELOPMENT COOPERATION EXPANDED CAPABILITIES ACCELERATED PIPELINE PIPELINE ENHANCEMENT Cell therapies, small molecules, and proteins Immuno-oncology combinations Deep translational capabilities Global commercializa

  27. Slide 27: Juno's goals for value creation

    Juno’s goals for value creation Execute Leukemia Potential First in Class: JCAR015 Adult ALL Potential Best in Class: JCAR017 Ped and Adult ALL CD19- Disease: JCAR018 Human CD19: JCAR021 Transform Lymphoma / CLL JCAR017 (NHL and CLL) JCAR014 PD-L1 Combination Beyond B Cell Malignancies to Myeloma an

  28. Slide 28: Program Description

    Program Description CD19: JCAR015 (Adult ALL and Adult NHL) Adult ALL Phase I Adult NHL (Post Autologous Tx) Phase I Adult ALL Phase II Pivotal Study CD19: JCAR017 (Pediatric ALL and Adult NHL) Pediatric ALL Phase I / II Adult NHL Phase I CD19: JCAR014 (Adult B Cell Malignancies) Adult B Cell Malign

Juno Therapeutics — Investor Presentation (July 2016) on 6ix